


In the editorial section, Steven J Hoffman et al. (66) argue for a binding international legal framework to address antimicrobial resistance. Steffan Crausaz (67) describes how New Zealand introduced competition among suppliers for medicines to treat rare disorders.

Fiona Fleck reports (70-71) on the difficulties of testing treatments for Ebola virus disease. In an interview, Cheikh Niang (72-73) explains why testing new vaccines, treatments and diagnostics in this context requires more than just a biomedical approach.



### **More accurate doses; less drug resistance**

Daniel J Hayes et al. (74-83) build a model to improve age-based dosing of antimalarials.

### **Banks of biological specimens**

Haidan Chen & Tikki Pang (113-117) call for global governance of these collections.

### **The high costs of health care**

Beverley M Essue et al. (102-112) review the evidence on ways to decrease household expenditure.

### **Beyond gross domestic product per capita**

Elliot Marseille et al. (118-124) discuss alternative approaches to setting cost-effectiveness thresholds.